Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;10(3):e00955.
doi: 10.1002/prp2.955.

Dynamic muscle paralytic effects of a novel botulinum toxin A free of neurotoxin-associated proteins

Wu-Chao Liu  1 , Jun-Hui Su  2   3 , Ya Feng  2 , Xue-Rui Xiang  2   3 , Li-Zhen Pan  2 , Ying Liu  2 , Lin Ma  2 , Zhi-Yu Nie  2 , Xue-Ping Zhang  4 , Ling-Jing Jin  1   3
Affiliations

Dynamic muscle paralytic effects of a novel botulinum toxin A free of neurotoxin-associated proteins

Wu-Chao Liu et al. Pharmacol Res Perspect. 2022 Jun.

Abstract

Structurally, botulinum toxin type A (BTX-A) is composed of neurotoxin and nontoxic complexing proteins (CPs), and the neurotoxin has the function of blocking acetylcholine release from the neuromuscular junction and therefore paralyzing muscles. Nowadays, a novel botulinum toxin A free of CPs (chinbotulinumtoxin A, A/Chin) is produced, and the present study comprehensively evaluated the dynamic paralytic effect of A/Chin on the gastrocnemius muscle of rats. Different doses (0.01, 0.1, 0.5, 1, 2, and 4 U) of A/Chin and other BTX-As with and without CPs were administered to the gastrocnemius muscles of rats and muscle strength was measured and compared at different postinjection timepoints (from day 0 to 84). With the dose increased, time-to-peak paralytic effect of other BTX-As varied from day 3 to day 14, while A/Chin groups showed rapid and steady time to peak on day 3. At the lowest dose of 0.01 U, A/Chin showed significantly better peak paralytic effect than the others on day 3. When the dose increased to 0.5 U and more, A/Chin group also showed significant paralytic effect when the paralytic effect of other BTX-As was worn off. Moreover, the paralytic effect of A/Chin was confirmed as muscle atrophy while hematoxylin-eosin staining was performed. In conclusion, compared with other BTX-As, A/Chin showed rapid and steady time-to-peak paralytic effect and long-term paralytic efficacy at the same dose level. And it might lay a solid foundation for further wide application of A/Chin in both clinical and cosmetic areas.

Keywords: botulinum toxin A; chinbotulinumtoxin A; complex proteins; muscle strength.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Dynamic paralytic effects of different doses of A/Chin on the gastrocnemius muscle strength of rats. **p < .01 and ***p < .001 for 0.01 U A/Chin versus the NS group. ## p < .01 and ### p < .001 for 4 U A/Chin versus the NS group. All data points represent mean ± SE
FIGURE 2
FIGURE 2
Right gastrocnemius muscle strength of rats after different doses of BTX‐As injection at three key timepoints. *p < .05, **p < .01 and ***p < .001 versus the NS group. # p < .05, ## p < .01 and ### p < .001 versus the 0.01 U A/Chin group. All columns represent mean ± SE
FIGURE 3
FIGURE 3
Hematoxylin–eosin staining of gastrocnemius muscle after injection of 2 U A/Chin and other BTX‐As for 28 days
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Alster TS, Harrison IS. Alternative clinical indications of botulinum toxin. Am J Clin Dermatol. 2020;21(6):855‐880. doi:10.1007/s40257-020-00532-0 - DOI - PubMed
    1. Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8):1131‐1138. doi:10.1002/mds.27072 - DOI - PubMed
    1. Dressler D. Five‐year experience with incobotulinumtoxinA (Xeomin((R))): the first botulinum toxin drug free of complexing proteins. Eur J Neurol. 2012;19(3):385‐389. doi:10.1111/j.1468-1331.2011.03559.x - DOI - PubMed
    1. Rupp D, Nicholson G, Canty D, et al. OnabotulinumtoxinA displays greater biological activity compared to incobotulinumtoxinA, demonstrating non‐interchangeability in both in vitro and in vivo assays. Toxins (Basel). 2020;12(6):393. doi:10.3390/toxins12060393 - DOI - PMC - PubMed
    1. Grein S, Mander GJ, Taylor HV. XeominÆ is stable without refrigeration: complexing proteins are not required for stability of botulinum neurotoxin type A preparations. Toxicon. 2008;51:13.

Publication types